Freitag, 3. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
SunRISe-3

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Rekrutierend

NCT-Nummer:
NCT05714202

Studienbeginn:
März 2023

Letztes Update:
24.04.2024

Wirkstoff:
TAR-200, Cetrelimab, BCG Vesiculture

Indikation (Clinical Trials):
Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Janssen Research & Development, LLC

Collaborator:
-

Studienleiter

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

Kontakt

Studienlocations
(3 von 234)

Urologicum Duisburg
47169 Duisburg
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitatsklinikum Erlangen
91054 Erlangen
(Bayern)
GermanyRekrutierend» Google-Maps
Universitatsklinikum Essen
45147 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Frankfurt
60590 Frankfurt am Main
(Hessen)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Freiburg
79106 Freiburg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Urologische Partnerschaft Koln UPK
50968 Köln
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Matthias Schulze - Germany
04416 Markkleeberg
(Sachsen)
GermanyRekrutierend» Google-Maps
Urologie Neandertal Praxis Mettmann
40822 Mettmann
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Kinderonkologisches Zentrum am Universitätsklinikum Münster
Albert-Schweitzer-Campus 1
48149 Münster
DeutschlandRekrutierend» Google-Maps
Klinikum rechts der Isar an der Technischen Universitat Munchen
81675 München
(Bayern)
GermanyRekrutierend» Google-Maps
Klinikum Nurnberg Nord
90419 Nuernberg
(Bayern)
GermanyRekrutierend» Google-Maps
Medizinisches Versorgungszentrum - Urologie
90491 Nurnberg
(Bayern)
GermanyRekrutierend» Google-Maps
Studienpraxis Urologie Nurtingen
72622 Nürtingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Caritas-Krankenhaus St. Josef
93053 Regensburg
(Bayern)
GermanyRekrutierend» Google-Maps
Universitat Tubingen
72076 Tübingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Genesis Research, LLC - West Coast Urology
90720 Los Alamitos
United StatesRekrutierend» Google-Maps
Cedars-Sinai Medical Center
90048 Los Angeles
United StatesRekrutierend» Google-Maps
UC Davis Comprehensive Cancer Center
95630 Sacramento
United StatesRekrutierend» Google-Maps
Providence Medical Foundation
95403 Santa Rosa
United StatesRekrutierend» Google-Maps
Colorado Clinical Research
80228 Lakewood
United StatesRekrutierend» Google-Maps
Urological Research Network
33016 Hialeah
United StatesRekrutierend» Google-Maps
Orlando Health Cancer Institute
32806 Orlando
United StatesRekrutierend» Google-Maps
Sarasota Memorial Hospital
34239 Sarasota
United StatesRekrutierend» Google-Maps
The Emory Clinic Department of Urology
30322 Atlanta
United StatesRekrutierend» Google-Maps
Northwestern University
60611 Chicago
United StatesRekrutierend» Google-Maps
AMR Kansas City Oncology
66204 Merriam
United StatesRekrutierend» Google-Maps
Chesapeake Urology Research Associates
21076 Hanover
United StatesRekrutierend» Google-Maps
Lahey Hospital & Medical Center
01805 Burlington
United StatesRekrutierend» Google-Maps
University of Michigan
48109 Ann Arbor
United StatesRekrutierend» Google-Maps
University Of Minnesota
55455 Minneapolis
United StatesRekrutierend» Google-Maps
Mayo Clinic Rochester
55905 Rochester
United StatesRekrutierend» Google-Maps
Cooper Health System MD Anderson Cancer Center at Cooper
08103 Camden
United StatesRekrutierend» Google-Maps
VA NY Harbor Healthcare System
10010 New York
United StatesRekrutierend» Google-Maps
Icahn School of Medicine at Mt. Sinai
10029 New York
United StatesRekrutierend» Google-Maps
Associated Medical Professionals of Ny
13210 Syracuse
United StatesRekrutierend» Google-Maps
SUNY Upstate Med Univ
13210 Syracuse
United StatesRekrutierend» Google-Maps
Vidant Urology - Greenville
27834 Greenville
United StatesRekrutierend» Google-Maps
Central Ohio Urology Group
43230 Gahanna
United StatesRekrutierend» Google-Maps
Centers for Advanced Urology LLC d b a MidLantic Urology
19004 Bala-Cynwyd
United StatesRekrutierend» Google-Maps
Thomas Jefferson University Hospital
19107 Philadelphia
United StatesRekrutierend» Google-Maps
UPMC Shadyside Hospital
15232 Pittsburgh
United StatesRekrutierend» Google-Maps
Carolina Urologic Research Center
29572 Myrtle Beach
United StatesRekrutierend» Google-Maps
Urology Clinics of North Texas
75231 Dallas
United StatesRekrutierend» Google-Maps
Houston Methodist Hospital
77030 Houston
United StatesRekrutierend» Google-Maps
Urology San Antonio Research
78229 San Antonio
United StatesRekrutierend» Google-Maps
Huntsman Cancer Institute
84112 Salt Lake City
United StatesRekrutierend» Google-Maps
George E. Wahlen VAMC
84148 Salt Lake City
United StatesRekrutierend» Google-Maps
Urology Of Virginia, Pllc
23462 Virginia Beach
United StatesRekrutierend» Google-Maps
Hospital Italiano de Buenos Aires
C1199 Buenos Aires
ArgentinaRekrutierend» Google-Maps
Sociedade Beneficente de Senhoras - Hospital Sírio Libanês
C1417 Buenos Aires
ArgentinaRekrutierend» Google-Maps
Centro Urologico Profesor Bengio
X5000KPH Cordoba
ArgentinaRekrutierend» Google-Maps
Hospital Privado - Centro Medico de Cordoba
X5016KEH Cordoba
ArgentinaRekrutierend» Google-Maps
Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
5000 Córdoba
ArgentinaRekrutierend» Google-Maps
Hospital Privado de la Comunidad
B7602CBM Mar del Plata
ArgentinaRekrutierend» Google-Maps
Instituto Medico Rio Cuarto
5800 Rio Cuarto
ArgentinaRekrutierend» Google-Maps
Macquarie University Hospital
2109 Macquarie University
AustraliaRekrutierend» Google-Maps
Hollywood Private Hospital
6009 Nedlands
AustraliaRekrutierend» Google-Maps
Mater Hospital Brisbane
4101 South Brisbane
AustraliaRekrutierend» Google-Maps
Centre Hospitalier de l'Ardenne
6800 Libramont-Chevigny
BelgiumRekrutierend» Google-Maps
GZA Ziekenhuizen- Campus St Augustinus
2610 Wilrijk
BelgiumRekrutierend» Google-Maps
NAIC - Nair Antunes Instituto do Câncer
17033-495 Bauru
BrazilRekrutierend» Google-Maps
Universidade Estadual De Campinas
13083-888 Campinas
BrazilRekrutierend» Google-Maps
Liga Paranaense de Combate ao Cancer
81520-060 Curitiba
BrazilRekrutierend» Google-Maps
Liga Norte Riograndense Contra O Cancer
59075-740 Natal
BrazilRekrutierend» Google-Maps
Irmandade Santa Casa de Misericordia de Porto Alegre
90050-170 Porto Alegre
BrazilRekrutierend» Google-Maps
Hospital Regional do Cancer - Hospital de Esperança
19013-050 Presidente Prudente
BrazilRekrutierend» Google-Maps
Hospital Ana Nery Santa Cruz do Sul
96835-090 Santa Cruz Do Sul
BrazilRekrutierend» Google-Maps
CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia
09060-870 Santo Andre
BrazilRekrutierend» Google-Maps
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
01246-000 Sao Paulo
BrazilRekrutierend» Google-Maps
Real e Benemérita Associação Portuguesa de Beneficência
1321-001 Sao Paulo
BrazilRekrutierend» Google-Maps
Fundacao Antonio Prudente A C Camargo Cancer Center
01508-010 São Paulo
BrazilRekrutierend» Google-Maps
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
05652-900 São Paulo
BrazilRekrutierend» Google-Maps
Nova Scotia Health Authority
B3H 2Y9 Halifax
CanadaRekrutierend» Google-Maps
St Josephs Healthcare Hamilton
L8N 4A6 Hamilton
CanadaRekrutierend» Google-Maps
Princess Margaret Cancer Centre University Health Network
M5G 1Z5 Toronto
CanadaRekrutierend» Google-Maps
CHUM - Centre hospitalier universitaire de Montreal
H2X 3E4 Montréal
CanadaRekrutierend» Google-Maps
Unite de Recherche Clinique du CISSS des Laurentides
J7Z 2V4 Saint Jerome Quebec
CanadaRekrutierend» Google-Maps
CHU de Quebec-Universite Laval-Hopital de l'Enfant-Jesus
G1J1Z4 Quebec
CanadaRekrutierend» Google-Maps
Peking University First Hospital
100034 Beijing
ChinaRekrutierend» Google-Maps
Beijing Luhe Hospital, Capital Medical University
101100 Beijing
ChinaRekrutierend» Google-Maps
Hunan Province Cancer Hospital
410013 Chang Sha
ChinaRekrutierend» Google-Maps
The First Bethune Hospital of Jilin University
130499 Changchun
ChinaRekrutierend» Google-Maps
West China Hospital Sichuan University
610044 Chengdu
ChinaRekrutierend» Google-Maps
Chongqing University Cancer Hospital
400000 Chongqing
ChinaRekrutierend» Google-Maps
People's Hospital of Deyang City
618000 Deyang City
ChinaRekrutierend» Google-Maps
Sun Yat-Sen University Cancer Center
430030 GuangZhou
ChinaRekrutierend» Google-Maps
Zhejiang Provincial People's Hospital
310000 Hangzhou
ChinaAbgeschlossen» Google-Maps
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
310016 Hangzhou
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital of Ningbo University
315010 Ningbo
ChinaRekrutierend» Google-Maps
Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
200025 Shanghai
ChinaRekrutierend» Google-Maps
Huadong Hospital Affiliated to Fudan University
200400 Shanghai
ChinaRekrutierend» Google-Maps
Shengjing Hospital of China Medical University
110004 Shenyang
ChinaRekrutierend» Google-Maps
The Second Hospital of Tianjin Medical University
300211 Tianjin
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital of Wenzhou Medical University
325000 Wenzhou
ChinaRekrutierend» Google-Maps
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
430030 Wuhan
ChinaRekrutierend» Google-Maps
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
710061 Xian
ChinaRekrutierend» Google-Maps
Fakultni nemocnice u sv. Anny v Brne
65691 Brno
CzechiaRekrutierend» Google-Maps
Fakultni nemocnice Hradec Kralove
500 05 Hradec Králové
CzechiaRekrutierend» Google-Maps
Krajská nemocnice Liberec a.s.
460 01 Liberec
CzechiaRekrutierend» Google-Maps
Fakultní nemocnice Olomouc
779 00 Olomouc
CzechiaRekrutierend» Google-Maps
Thomayerova nemocnice, Onkologicka klinika
140 59 Praha 4
CzechiaRekrutierend» Google-Maps
Fakultni nemocnice Kralovske Vinohrady
100 34 Praha
CzechiaRekrutierend» Google-Maps
Polyclinique Bordeaux Nord Acquitaine
33000 Bordeaux
FranceRekrutierend» Google-Maps
CHU Gabriel-Montpied
63003 Clermont-Ferrand
FranceRekrutierend» Google-Maps
Polyclinique de Limoges - Francois Chenieux
87000 Limoges
FranceRekrutierend» Google-Maps
Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
45067 Orléans
FranceRekrutierend» Google-Maps
Groupe Hospitalier Diaconesses Croix Saint Simon
75960 PARIS cedex 20
FranceRekrutierend» Google-Maps
Hôpital Universitaire Pitié-Salpêtrière
75013 Paris
FranceRekrutierend» Google-Maps
Hopital Europeen Georges-Pompidou
75015 Paris
FranceRekrutierend» Google-Maps
APHP - Hopital Bichat - Claude Bernard
75018 Paris
FranceRekrutierend» Google-Maps
Clinical La Croix Du Sud - Ramsay Santé
31130 Quint-Fonsegrives
FranceRekrutierend» Google-Maps
Chu Rennes - Hopital Pontchaillou
35000 Rennes
FranceRekrutierend» Google-Maps
Institut de Cancerologie Strasbourg Europe ICANS
67200 Strasbourg
FranceRekrutierend» Google-Maps
Health Care Global Enterprises pvt Ltd
560027 Bangalore
IndiaRekrutierend» Google-Maps
Post Graduate Institute of Medical Education & Research (PGIMER)
160012 Chandigarh
IndiaRekrutierend» Google-Maps
Netaji Subhas chandra Bose Cancer Research Institute
700094 Kolkata
IndiaRekrutierend» Google-Maps
CIMET's Inamdar Multispeciality Hospital
411040 Pune
IndiaRekrutierend» Google-Maps
Generale Regionale F. Miulli
70021 Acquaviva delle Fonti
ItalyRekrutierend» Google-Maps
Ospedale San Giuseppe Moscati di Avellino
83100 Avellino
ItalyRekrutierend» Google-Maps
Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
31033 Castelfranco Veneto
ItalyRekrutierend» Google-Maps
Ospedale San Raffaele di Milano
20132 Milano
ItalyRekrutierend» Google-Maps
Fondazione G. Pascale - Istituto Nazionale Tumori IRCCS
80138 Napoli
ItalyRekrutierend» Google-Maps
Istituto Nazionale Tumori Regina Elena
00128 Rome
ItalyRekrutierend» Google-Maps
Fuji City General Hospital
417-8567 Fuji-shi
JapanRekrutierend» Google-Maps
Kanazawa University Hospital
920-8641 Kanazawa
JapanRekrutierend» Google-Maps
Nara Medical University Hospital
634-8522 Kashihara-shi
JapanRekrutierend» Google-Maps
Kobe City Medical Center General Hospital
650 0047 Kobe City
JapanRekrutierend» Google-Maps
National Hospital Organization Kumamoto Medical Center
860-0008 Kumamoto-shi
JapanRekrutierend» Google-Maps
Nagano Municipal Hospital
381-8551 Nagano-shi
JapanRekrutierend» Google-Maps
Nagasaki University Hospital
852-8501 Nagasaki-shi
JapanRekrutierend» Google-Maps
JRC Nagasaki Genbaku Hospital
852-8511 Nagasaki-Shi
JapanRekrutierend» Google-Maps
Saiseikai Narashino Hospital
275-8580 Narashino-shi
JapanRekrutierend» Google-Maps
Toyama University Hospital
930-0194 Toyama-shi
JapanRekrutierend» Google-Maps
Yokohama City University Medical Center
232 0024 Yokohama
JapanRekrutierend» Google-Maps
Pusan National University Hospital
49241 Busan
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Chungbuk National University Hospital
28644 Cheongju
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Kyungpook National University Chilgok Hospital
41404 Daegu
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Keimyung University Dongsan Hospital
42601 Daegu
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
National Cancer Center
10408 Gyeonggi-do
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Chonnam National University Hwasun Hospital
58128 Jeollanam-do
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Korea University Anam Hospital
02841 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Kangbuk Samsung Hospital
03181 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Severance Hospital Yonsei University Health System
03722 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Samsung Medical Center
06351 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
The Catholic University of Korea Seoul St. Mary's Hospital
06591 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Consultorio Medico dentro del Hospital Angeles Acoxpa
14308 Ciudad de México
MexicoRekrutierend» Google-Maps
Hospital Universitario Dr Jose Eleuterio Gonzalez
64460 Monterrey
MexicoRekrutierend» Google-Maps
Avix Investigacion Clinica S C
64710 Monterrey
MexicoRekrutierend» Google-Maps
Canisius-Wilhelmina Ziekenhuis
6524 KD Nijmegen
NetherlandsRekrutierend» Google-Maps
Uniwersytecki Szpital Kliniczny w Bialymstoku
15-276 Bialystok
PolandRekrutierend» Google-Maps
Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ
20-708 Lublin
PolandRekrutierend» Google-Maps
Centrum Medyczne
97-300 Piotrkow Trybunalski
PolandRekrutierend» Google-Maps
Clinical Research Center sp z o o MEDIC R s k
61 731 Poznan
PolandRekrutierend» Google-Maps
Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka,
76-200 Slupsk
PolandRekrutierend» Google-Maps
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
02-781 Warszawa
PolandRekrutierend» Google-Maps
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
50-556 Wroclaw
PolandRekrutierend» Google-Maps
Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE
3000-075 Coimbra
PortugalRekrutierend» Google-Maps
Centro Hospitalar de Lisboa Norte Hospital Santa Maria
1649 028 Lisboa
PortugalRekrutierend» Google-Maps
Centro Hospitalar de Vila Nova de Gaia Espinho E P E
4434 502 Vila Nova de Gaia
PortugalRekrutierend» Google-Maps
Hosp. Gral. Univ. de Castellon
12004 Castellon
SpainRekrutierend» Google-Maps
Hosp. Univ. de Bellvitge
08907 L'Hospitalet de Llobregat
SpainRekrutierend» Google-Maps
Hosp. Univ. Marques de Valdecilla
39008 Santander
SpainRekrutierend» Google-Maps
Hosp. Clinico Univ. de Valencia
46010 Valencia
SpainRekrutierend» Google-Maps
Kaohsiung Medical University Chung-Ho Memorial Hospital
807 Kaohsiung City
TaiwanRekrutierend» Google-Maps
China Medical University Hospital
404 Taichung City
TaiwanRekrutierend» Google-Maps
Taichung Veterans General Hospital
40705 Taichung
TaiwanRekrutierend» Google-Maps
Taipei Veterans General Hospital
11217 Taipei
TaiwanRekrutierend» Google-Maps
Linkou Chang Gung Memorial Hospital
33382 Taoyuan
TaiwanRekrutierend» Google-Maps
Western General Hospital
EH4 2XU Edinburgh
United KingdomRekrutierend» Google-Maps
St. Bartholomew's Hospital
EC1A 7BE London
United KingdomRekrutierend» Google-Maps
The Royal Marsden NHS Trust
SW3 6JJ London
United KingdomRekrutierend» Google-Maps
Charing Cross Hospital
W6 8RF London
United KingdomRekrutierend» Google-Maps
Derriford Hospital
PL6 8DH Plymouth
United KingdomRekrutierend» Google-Maps
Scunthorpe General Hospital
DN15 7BH Scunthorpe
United KingdomRekrutierend» Google-Maps
Sheffield Teaching Hospitals NHS Foundation Trust
S10 2JF Sheffield
United KingdomRekrutierend» Google-Maps
Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
TR1 3LJ Truro
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder

cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have

HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery

system regulated as an investigational drug. The drug constituent consists of gemcitabine and

osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4)

kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay

of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by

intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine,

delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared

against intravesical BCG. The study consists of a Screening phase, Treatment phase, and

Follow-up phase. The total duration of the study will be up to 5 years and 2 months.

Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time

points during the study.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Histologically confirmed initial diagnosis by local pathology (within 90 days of the

most recent signed informed consent) of high grade non-muscle invasive bladder cancer

(HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are

Bacillus Calmette Guérin (BCG)-naïve

- BCG-naïve (participants who have not received prior intravesical BCG or who previously

received but stopped BCG more than 3 years before date of randomization are eligible)

- All visible papillary disease must be fully resected (absent) prior to date of

randomization and documented at baseline cystoscopy. Local urine cytology at screening

must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients

with papillary only disease (without CIS)

- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2

- All adverse events associated with any prior surgery and/or intravesical therapy must

have resolved to common terminology criteria for adverse events (CTCAE) version 5.0

Grade less than (<) 2 prior to date of randomization

- Participants must be willing to undergo all study procedures

Exclusion Criteria:

- Presence or history of histologically confirmed, muscle invasive, locally advanced,

nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to

[>=] T2)

- Must not have had urothelial carcinoma or histological variant at any site outside of

the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the

upper urinary tract (including renal pelvis and ureter) is allowable if treated with

complete nephroureterectomy more than 24 months prior to randomization

- Presence of any bladder or urethral anatomic feature (example, urethral stricture)

that, in the opinion of the investigator, may prevent the safe insertion, indwelling

use, removal of TAR-200 or administration of intravesical BCG. Participants with

tumors involving the prostatic urethra in men will be excluded

- A history of clinically significant polyuria with recorded 24-hour urine volumes

greater than 4000 milliliters (mL)

- Indwelling catheters are not permitted; however, intermittent catheterization is

acceptable

Studien-Rationale

Primary outcome:

1. Event-free Survival (EFS) (Time Frame - Up to 5 years 2 months):
EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to [>=] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first.



Secondary outcome:

1. Overall Complete Response (CR) Rate (Time Frame - Up to 5 years 2 months):
Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months.

2. Duration of CR (Time Frame - Up to 5 years 2 months):
Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR.

3. Recurrence-Free Survival (RFS) (Time Frame - Up to 5 years 2 months):
RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first.

4. Time to Progression (TTP) (Time Frame - Up to 5 years 2 months):
TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first.

5. Overall Survival (OS) (Time Frame - Up to 5 years 2 months):
OS is defined as the time from randomization to death, due to any cause.

6. Cancer Specific Survival (CSS) (Time Frame - Up to 5 years 2 months):
CSS is defined as the time from randomization to the date of death due to bladder cancer.

7. Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE) (Time Frame - Up to 5 years 2 months):
Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event.

8. Number of Participants with Adverse Events (AEs) (Time Frame - Up to 5 years 2 months):
Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

9. Number of Participants with Change from Baseline in Laboratory Abnormalities (Time Frame - Up to 5 years 2 months):
Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event.

10. Number of Participants with Change from Baseline in Vital Signs Abnormalities (Time Frame - Up to 5 years 2 months):
Number of participants with change from baseline in vital signs (blood pressure [systolic and diastolic], heart rate, temperature, and weight) abnormalities will be reported.

11. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24 (Time Frame - Up to 5 years 2 months):
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

12. Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores (Time Frame - Up to 5 years 2 months):
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

Studien-Arme

  • Experimental: Treatment Group A: TAR-200 + Cetrelimab
    Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.
  • Active Comparator: Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture
    Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance).
  • Experimental: Treatment Group C: TAR-200 Alone
    Participants will receive intravesical TAR-200 alone once Q3W.

Geprüfte Regime

  • TAR-200 (JNJ-17000139):
    TAR-200 will be administered intravesically.
  • Cetrelimab (JNJ-63723283):
    Cetrelimab will be administered.
  • BCG Vesiculture:
    BCG will be administered intravesically.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.